schizophrenia
Conditions
Interventions
Control group:Risperidone4~6mg/d
Experimental group A:Risperidone 4~6mg/d, Celecoxib 200mg/d
Experimental group B:Risperidone 4~6mg/d, Celecoxib 400mg/d
Sponsors
Jingzhou Mental Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 44 Years
Inclusion criteria
Inclusion criteria: Eligible participants in the study were 90 patients with chronic schizophrenia with age ranging from 18 to 44 years. All participants were inpatients, in the active phase of illness, and met DSM-IV criteria for schizophrenia.The course of disease is more than one year and the total duration is less than five years. All patients were free of any infection and autoimmune disease for at least two weeks, had normal complete blood counts, hepatic and renal panels and negative toxicological screens. The minimum score of 60 on Positive and Negative Syndrome Scale (PANSS) will be required.
Exclusion criteria
Exclusion criteria: Patient will be excluded from the study if they had a clinically significant organic and neurological disorder, current abuse or dependence on drugs within 6 months, peptic ulcer disease or a history of gastrointestinal bleeding, use of any medications identified as contradicted with COX-2 inhibitors. Pregnant or lactating women; Patient received neuroleptics orally within one week or depot neuroleptic within two months before the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognition; | — |
Secondary
| Measure | Time frame |
|---|---|
| PANSS??;IL-1;IL-4;IL-6;CRP;TNF-a;TESS; | — |
Countries
China
Contacts
Public ContactFeng Liu
Jingzhou Mental Hospital
Outcome results
None listed